Stock Financial Ratios, Dividends, Split History
LM / Legg Mason, Inc. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.
|Market Cap ($M)||3,436.56|
|Enterprise Value ($M)||3,436.56|
|Book Value / Share||n/a|
|Price / Book||n/a|
|NCAV / Share||0.00|
|Price / NCAV||n/a|
|Repurchased And Retired Shares Excluded From Weighted Average Shares Outstanding||6,005,000|
|Weighted Average Number Diluted Shares Outstanding Adjustment||6,335,000|
|Common Shares Outstanding||95,860,683|
|Common Stock Shares Outstanding||95,727,000|
|Altman Z Score||N/A|
|Beneish M Score||N/A|
|Management Effectiveness (mra)|
|Return on Invested Capital (ROIC)||n/a|
|Return on Assets (ROA)||n/a|
|Return on Equity (ROE)||n/a|
|Income Statement (mra) ($M)|
|Cash Flow Statement (mra) ($M)|
|Cash from Investing||0.00|
|Identifiers and Descriptors|
|Central Index Key (CIK)||704051|
|524901955 524901501 524901905|
|SIC 6282 - Investment Advice|
Stock splits are used by Legg Mason, Inc. to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.
2018-06-22 - Asif
Overview Cascadian Therapeutics is a clinical-stage biopharmaceutical company focused on the development of therapeutic products for the treatment of cancer. The company's goal is to develop and commercialize novel targeted compounds that have the potential to improve the lives and outcomes of cancer patients. The company's lead clinical-stage product candidate is tucatinib, an oral, HER2-selective small molecule tyrosine kinase inhibitor. The company's pipeline also includes two preclinical-stage product candidates: CASC-578, a Chk1 kinase inhibitor, and CASC-674, an antibody program against an immuno-oncology target known as TIGIT. 2018 Merger Agreement On January 30, 2018, the company entered into an Agreement and Plan of Merger (the Merger Agreement) with Seattle Genetics, Inc., a Delaware corporation (Seattle Genetics), and Valley Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Seattle Genetics (Merger Sub). Pursuant to the Merger ...
2018-06-22 - Asif
Business Overview The Corporation is a Delaware corporation, a bank holding company (BHC) and a financial holding company. When used in this report, “the Corporation” may refer to Bank of America Corporation individually, Bank of America Corporation and its subsidiaries, or certain of Bank of America Corporation’s subsidiaries or affiliates. The company's principal executive offices are located in Charlotte, North Carolina. Through its banking and various nonbank subsidiaries throughout the U.S. and in international markets, the company provide a diversified range of banking and nonbank financial services and products through four business segments: Consumer Banking, Global Wealth & Investment Management (GWIM), Global Banking and Global Markets, with the remaining operations recorded in All Other. The company operate its banking activities primarily under the Bank of America, National Association (Bank of America, N.A. or BANA) charter. At March 31, 2018, the Corporation had a...
2018-06-18 - Asif
Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...
Related News Stories
Legg Mason Inc.’s (LM - Free Report) chief executive officer (CEO) Joseph A. Sullivan’s total compensation, including a cash bonus, had been increased to $9.7 million in fiscal 2018. This represents a jump of 8% from the prior fiscal on higher incentives, according to a regulatory filing of Jun 20. In fiscal 2018, Sullivan’s pay package included salary of $500,000, unchanged from fiscal 2017, a cash bonus of $4 million (up from $3. (20-0)
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world. (84-0)
Shares of Chevron Corporation (CVX - Free Report) , which has survived the worst oil crash in more than 50 years, now sit near 52-week highs. The blue-chip energy company is up more than 100% off its August 2015 lows and poised for further capital appreciation, riding on its healthy earnings growth prospects. (46-0)
Amazon.com Inc. (AMZN - Free Report) continues to expand its two-hour Whole Food delivery Service. Baltimore, Boston, Philadelphia and Richmond are the latest additions to the list of cities receiving this service. (111-0)
Lilis Energy, Inc. (LLEX - Free Report) recently entered into an acreage swap transaction in a bid to upgrade its portfolio in the Permian Basin. The pure-play Permian operator is set to trade its non-operated holdings with 1,500 acres of West Texas land in the Delaware Basin. The company, with which it has entered into the swap deal, has not been undisclosed yet. Subject to satisfactory closing conditions, the deal is set for closure by the end of July. (34-0)
as of ET